The GSTM111, XPD c.934G>A9–11, XPD c.2251A>C9,10,12, FAS c.-671A>G13 and FASL c.-844C>T13 SNVs altered relapse-free (RFS), disease-free (DFS), event-free survival (EFS) and/or overall survival (OS) of HNSCC and oropharynx SCC patients treated with CDDP and/or RT, respectively. This evidence concerns the gene FAS and head and neck squamous cell carcinoma.